DAGCO Inc’s Roivant Sciences ROIV Stock Holding History

DAGCO Inc’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,400	Closed	-$27K	–	354
2023 Q4	$27K	Buy	+2,400	New	+$23.4K	0.02%	140

Other funds holding ROIV

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

DAGCO Inc's ROIV Position: Q1 2024 in Review

DAGCO Inc sold out of Roivant Sciences (ROIV) in Q1 2024, closing a stake of 2,400 shares — an estimated $27K sold.

DAGCO Inc first reported a position in ROIV in Q4 2023 and held it in 1 quarter. The position peaked at $27K in Q4 2023. 259 funds tracked by Wall St. Rank hold ROIV as of Q1 2024.

DAGCO Inc reported no remaining Roivant Sciences position as of Q1 2024 after selling out during the quarter.
DAGCO Inc sold 2,400 Roivant Sciences shares in Q1 2024, an estimated $27K.
DAGCO Inc first reported a position in Roivant Sciences in Q4 2023 and held it in 1 quarter.
DAGCO Inc's Roivant Sciences position peaked at $27K in Q4 2023.
259 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2024.

Based on DAGCO Inc's 13F filing for Q1 2024, filed 15 May 2024.